Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants.

BACKGROUND Pertussis booster vaccine (Tdap) recommendations assume that pertussis-specific antibodies in women immunized preconception, during, or after previous pregnancies persist at sufficient levels to protect newborn infants. METHODS Pertussis-specific immunoglobulin G (IgG) was measured by IgG-specific enzyme-linked immunosorbent assay (ELISA) in maternal-umbilical cord serum pairs where mothers received Tdap during the prior 2 years. Geometric mean concentrations (GMCs) of pertussis antibodies and cord-maternal GMC ratios were calculated. RESULTS One hundred five mothers (mean age, 25.3 years [range, 15.3-38.4 years]; mean gestation, 39 weeks [range, 37-43 weeks]) immunized with Tdap vaccine a mean of 13.7 months (range, 2.3-23.9 months) previously were included; 72 (69%) had received Tdap postpartum, 31 at a routine healthcare visit and 2 as contacts of another newborn. There was no difference in GMCs for pertussis-specific IgG in maternal delivery or infant cord sera for women immunized before (n = 86) or during (n = 19) early pregnancy. Placental transport of antibodies was 121%-186% from mothers immunized before and during pregnancy, respectively. Estimated GMC of IgG to pertussis toxin was <5 ELISA units (EU)/mL at infant age 2 months (start of infant immunization series). More infants of mothers immunized during pregnancy had pertussis toxin levels estimated to be higher than the lower limit of quantitation of the assay (4 EU/mL) through age 2 months (52% vs 38%; P = .34). CONCLUSIONS Infants of mothers immunized preconception or in early pregnancy have insufficient pertussis-specific antibodies to protect against infection. Maternal immunization during the third trimester, immunization of other infant contacts, and reimmunization during subsequent pregnancies may be necessary.

[1]  S. Gall.  Prevention of pertussis, tetanus, and diphtheria among pregnant, postpartum women, and infants. , 2012, Clinical obstetrics and gynecology.

[2]  Kathleen Gallagher,et al.  Summary of notifiable diseases -- United States, 2010 , 2012 .

[3]  S. Greene,et al.  Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. , 2012, Vaccine.

[4]  David Martin,et al.  Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system. , 2012, Vaccine.

[5]  C. Baker,et al.  Infant pertussis: what to do next? , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Englund,et al.  Infant pertussis: is cocooning the answer? , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Kimp Walton,et al.  Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System. , 2011, American journal of obstetrics and gynecology.

[8]  N. Hens,et al.  Effect of a Prepregnancy Pertussis Booster Dose on Maternal Antibody Titers in Young Infants , 2011, The Pediatric infectious disease journal.

[9]  M. Pichichero,et al.  Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. , 2011, American journal of obstetrics and gynecology.

[10]  C. Baker,et al.  Implementation of cocooning against pertussis in a high-risk population. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  S. Halperin,et al.  The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: Experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. , 2010, Vaccine.

[12]  A. DeMaria,et al.  Vaccinate the village. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  D. Greeff,et al.  Epidemiology of pertussis in the Netherlands and implications for future vaccination strategies , 2010 .

[14]  C. Byington,et al.  Pertussis antibodies in postpartum women and their newborns , 2010, Journal of Perinatology.

[15]  S. Black,et al.  Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines , 2009, The Lancet.

[16]  C. Baker,et al.  Pertussis immunization in a high-risk postpartum population. , 2009, Vaccine.

[17]  E. Walter,et al.  Cocooning infants: Tdap immunization for new parents in the pediatric office. , 2009, Academic pediatrics.

[18]  R. Holman,et al.  Infant and Maternal Risk Factors for Pertussis-Related Infant Mortality in the United States, 1999 to 2004 , 2009, The Pediatric infectious disease journal.

[19]  Shetal I Shah,et al.  Administration of Tetanus, Diphtheria, and Acellular Pertussis Vaccine to Parents of High-Risk Infants in the Neonatal Intensive Care Unit , 2008, Pediatrics.

[20]  S. Rasmussen,et al.  Non‐genetic risk factors for gastroschisis , 2008, American journal of medical genetics. Part C, Seminars in medical genetics.

[21]  J. Iskander,et al.  Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2008, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[22]  G. Wallace,et al.  Pertussis Hospitalizations Among Infants in the United States, 1993 to 2004 , 2008, Pediatrics.

[23]  F. Mooi,et al.  The case for maternal vaccination against pertussis. , 2007, The Lancet. Infectious diseases.

[24]  J. Iskander,et al.  Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[25]  Russell S Kirby,et al.  National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. , 2006, Birth defects research. Part A, Clinical and molecular teratology.

[26]  K. Edwards,et al.  Pertussis serostatus among neonates born to Hispanic women. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  D. Burwen,et al.  Comparing data mining methods on the VAERS database , 2005, Pharmacoepidemiology and drug safety.

[28]  O. Bilukha,et al.  Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[29]  J. Englund,et al.  Role of Maternal Pertussis Antibodies in Infants , 2005, The Pediatric infectious disease journal.

[30]  K. Edwards,et al.  Establishment of Diagnostic Cutoff Points for Levels of Serum Antibodies to Pertussis Toxin, Filamentous Hemagglutinin, and Fimbriae in Adolescents and Adults in the United States , 2004, Clinical Diagnostic Laboratory Immunology.

[31]  K. Ehresmann,et al.  Infant Pertussis: Who Was the Source? , 2004, The Pediatric infectious disease journal.

[32]  K. Edwards,et al.  Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. , 2004, The Journal of infectious diseases.

[33]  Robert T. Chen,et al.  Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. , 2004, The Pediatric infectious disease journal.

[34]  Masahiro Tanaka,et al.  Trends in pertussis among infants in the United States, 1980-1999. , 2003, JAMA.

[35]  M. Kruger,et al.  Seroprevalence of Bordetella pertussis antibodies in mothers and their newborn infants. , 2003, Infectious diseases in obstetrics and gynecology.

[36]  H. Hallander,et al.  Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. , 2003, Vaccine.

[37]  C. Vitek,et al.  Increase in deaths from pertussis among young infants in the United States in the 1990s , 2003, The Pediatric infectious disease journal.

[38]  S. Evans,et al.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports , 2001, Pharmacoepidemiology and drug safety.

[39]  R. Schneerson,et al.  Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. , 2000, The Journal of infectious diseases.

[40]  A. Czeizel,et al.  Tetanus toxoid and congenital abnormalities , 1999, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[41]  H. Hallander,et al.  Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. , 1998, Vaccine.

[42]  T. Kenyon,et al.  Risk factors for pertussis in young infants during an outbreak in Chicago in 1993. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  M. Pichichero,et al.  The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. , 1995, Pediatrics.

[44]  S. Cochi,et al.  The Vaccine Adverse Event Reporting System (VAERS). , 1994, Vaccine.

[45]  T. Moore,et al.  The amniotic fluid index in normal human pregnancy. , 1990, American journal of obstetrics and gynecology.

[46]  K. Edwards,et al.  Natural history of pertussis antibody in the infant and effect on vaccine response. , 1990, The Journal of infectious diseases.

[47]  J. A. Lichty,et al.  AN ATTEMPT TO INCREASE RESISTANCE TO PERTUSSIS IN NEWBORN INFANTS BY IMMUNIZING THEIR MOTHERS DURING PREGNANCY. , 1938, The Journal of clinical investigation.

[48]  K. Edwards,et al.  How can we best prevent pertussis in infants? , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  C. Baker,et al.  Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  G. Garnett,et al.  ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES , 2006 .

[51]  S. Gall.  Maternal immunization. , 2003, Obstetrics and gynecology clinics of North America.

[52]  Samuel L. Groseclose,et al.  Summary of Notifiable Diseases, United States. , 1997 .

[53]  V. Cáceres,et al.  Safety of tetanus toxoid in pregnant women: a hospital-based case-control study of congenital anomalies. , 1995, Bulletin of the World Health Organization.